In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.
The heavyweight is a network meta-analysis of 28 randomized controlled trials covering 3,058 adults, which…
So, will Texas legalize? Maybe not in 2027. But the people who blocked it are…
Struggling cannabis farms are eyeing a second life as data centers. The grow room you…
Low-dose THC beverages typically contain somewhere between 2 and 5 mg of THC per serving.…
A few dozen strangers answered one question, and here's what they told me. Cannabis rarely…
Federal officials admitted under oath at the DEA marijuana rescheduling hearing that the 54-year-old test…